ICYMI: Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/29HupHHOW6